The Department of Defense (DOD) solicits quotations for pharmaceutical agents to establish a Uniform Formulary (UF) within the Military Health System. As mandated by law, the DOD's Pharmacy and Therapeutics (P&T) Committee evaluates the clinical and cost-effectiveness of drugs to classify them as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary. Manufacturers may submit offers to reduce costs during the review period. The Request for Quotation (RFQ) outlines steps for submission, including utilizing a dataset and National Drug Code (NDC) Price List, with specific guidance for Blanket Purchase Agreements (BPA) and Additional Discount Programs (ADP). Notably, each quote must detail pricing, adherence to Federal Supply Schedule (FSS) standards, and compliance with the Drug Price Competition and Patent Term Restoration Act. The DOD reserves the right to reject certain formulations based on effectiveness assessments. All offered prices must be competitive, ensuring alignment with the established federal pricing frameworks. This structured approach aims to optimize pharmaceutical procurement, ensuring efficient utilization of government resources while maintaining high standards of beneficiary care in military healthcare facilities.

The document is an amendment to Solicitation HT9402-25-Q-9203 issued by the Defense Health Agency, dated April 1, 2025. Its primary purpose is to update the Newly Approved Drug (NAD) list and the Pre-Quotation Teleconference Meeting Agenda associated with the solicitation. Notable changes include the reclassification of Alhemo from "Antihemophilic Factors" to "Antihemophilic Agents" and the modification of Raldesy's classification to "Antidepressants and Non-Opioid Pain Syndrome Agents." These updates are meant to ensure that stakeholders have accurate and current information related to the drug classifications under consideration. Aside from these alterations, all other terms and conditions of the solicitation remain unchanged. The amendment underscores the agency's commitment to maintaining updated information to facilitate a smooth quoting process for potential contractors and is relevant within the framework of federal procurement processes for healthcare-related products.

The amendment to solicitation HT9402-25-Q-9203 from the Defense Health Agency announces the addition of Vykat XR to the Newly Approved Drug (NAD) List and outlines changes to submission deadlines. Specifically, the due date for quotes and responses to clinical questions has been extended from April 17 to April 24, 2025. An updated price list for Vykat XR has been incorporated into the solicitation documentation. All other conditions stated in the original solicitation remain unchanged. This amendment is crucial for ensuring stakeholders have adequate time to submit their quotes and questions, thereby promoting transparency and competition in the procurement process.

The document outlines the process for the formulary placement of newly FDA-approved innovator drugs within the TRICARE Pharmacy Benefits Program, following the Final Rule published on July 27, 2015. It delineates that the Pharmacy and Therapeutics (P&T) Committee has up to 120 days to recommend tier placement, categorizing innovator drugs as Tier 1 to 4 based on clinical and cost-effectiveness. FDA-approved drugs post-August 26, 2015, start as pending and may initially be accessed at higher Tier 3 copays unless medical necessity is justified. Price concessions can be submitted by manufacturers during three solicitation windows before quarterly reviews, with the final approval of tier placements resting with the DHA Director. The document also explicitly states that clinical presentations from manufacturers will not be entertained due to the volume of approvals. This procedural framework is essential in managing medication costs and ensuring the timely availability of innovative treatments for military personnel and their families.

The Price Appendix FAQ provides essential guidelines for submitting drug pricing information to a Pharmacy and Therapeutics (P&T) committee, focusing on the Best Price Agreement (BPA), Average Discount Price (ADP) for non-FAMP and WAC discounts. The document outlines critical steps, including filling in designated yellow cells in provided tables for up to 10 National Drug Codes (NDCs) with auto population features for pricing calculations. Specific instructions clarify how to indicate non-submission for quotes by utilizing color highlights, along with formulas for calculations of price per unit and total refunds. The P&T committee's decision-making process is emphasized, with contact points provided for further assistance. This document supports government procurement processes and ensures accurate, streamlined submissions of drug pricing, vital for compliance with RFP requirements at federal and state levels.

The document outlines the tentative agenda for the Department of Defense (DoD) Pharmacy and Therapeutics (P&T) Committee meeting scheduled for May 7-8, 2025, which will review antihemophilic agents in the non-factor category. Manufacturers must submit quotes for various drug formulations and plan to finalize their participation by April 17, 2025. It emphasizes procedures for price quotations, with notes highlighting that non-generic products may be designated with preferential pricing statuses. Additionally, the document refers to a blanket purchase agreement regarding newly approved drugs and an additional discount program aimed at offering TRICARE retail refunds, reinforcing the intent to enhance the value of products reimbursed by the program. There are provisions for potentially excluding low-value products from the TRICARE pharmacy benefit program altogether. The document serves as a vital guide for manufacturers and participants in the procurement of pharmaceutical agents, ensuring adherence to regulations and guidelines while maintaining cost-effectiveness in military healthcare services.

The document outlines the details for the Department of Defense's (DOD) Uniform Formulary class focusing on oncological agents, set to be discussed in the upcoming Pharmacy and Therapeutics (P&T) Committee meeting scheduled for May 7-8, 2025. It emphasizes the submission of quotes, due by April 17, 2025, for newly approved drugs, classified into two categories: uniform formulary and non-formulary agents. Specific drug details, including National Drug Codes (NDCs), package sizes, and pricing scenarios, are provided, most notably indicating "no quote" for all listed agents, which suggests that suppliers have yet to respond. The document also highlights potential considerations for Preferential Status, which could allow for non-generic agents to be treated as generic for cost-sharing, alongside discussions about step therapy and reimbursement methods aimed at promoting high-value products. Notes for manufacturers indicate the importance of completing required documentation in submitting their quotes. This comprehensive framework is part of the DOD’s efforts to manage healthcare costs while ensuring access to necessary oncological treatments for military personnel and their families. Overall, the document serves as an essential guide for pharmaceutical manufacturers participating in the quotation process for DOD's formulary needs.

The Department of Defense (DOD) is preparing for a Pharmacy and Therapeutics (P&T) Committee Meeting scheduled for May 7-8, 2025, focusing on newly approved diuretic drugs as part of its Uniform Formulary Program. Quotes for these drugs must be submitted by April 17, 2025. The document outlines specific drug categories, including Uniform and Non-Formulary statuses, National Drug Code (NDC) numbers, pricing, and packaging details, although no quotes have been received thus far. Key notes highlight the potential for agents to be subject to prior authorization, as well as the possibility of the P&T Committee recommending preferential treatment for certain non-generic pharmaceuticals to encourage the use of high-value products. An Additional Discount Program for these drugs offers tiers for pricing structure under TRICARE retail, further emphasizing the need for manufacturers to adhere to submission protocols, including fully executed signature pages. The summary conveys the overall intent of the DOD to efficiently manage pharmaceutical offerings for military treatment facilities and ensure compliance with regulatory frameworks surrounding drug selection and pricing.

The document discusses the Department of Defense (DoD) Uniform Formulary relating to newly approved drugs categorized under "Targeted Immunomodulatory Biologics," specifically in the subclass "Interleukin 23." A Pharmacy and Therapeutics (P&T) Committee meeting is scheduled for May 7-8, 2025, with all quotes due by April 17, 2025. It includes details of a Blanket Purchase Agreement (BPA) for multiple drugs, emphasizing the price per unit, dosage forms, and package sizes but indicating a lack of quoted prices for the listed medications. Notably, the document outlines procedures for prior authorization and step therapy as mechanisms to ensure effective medication utilization within military treatment facilities. It also addresses reimbursement methodologies that favor high-value products while potentially excluding lower-value alternatives from the TRICARE pharmacy benefit program. The P&T Committee may reconsider step preferences for certain agents, for example, adalimumab used in treating conditions like psoriasis and inflammatory bowel disease (IBD). This document serves as a guideline for drug procurement and reimbursement processes that support cost-effective healthcare within the military.

The Department of Defense (DoD) is preparing for a Pharmacy and Therapeutics (P&T) Committee Meeting on May 7-8, 2025, focusing on newly approved targeted immunomodulatory biologics within the interleukin-23 subclass. Quotes for these drugs are due by April 17, 2025. The document discusses various aspects of pricing and formulary scenarios for these drugs, including a blanket purchase agreement appendix. Key details include the absence of quotes for several specified National Drug Codes (NDCs) and the implications of prior authorization requirements, as well as step therapy protocols for new patients. The P&T Committee may recommend preferential status for some non-generic agents, treating them as generics for cost-sharing purposes. The document emphasizes the importance of compliance with various guidelines while streamlining the purchasing process through potential discounts and rebates. Overall, the document outlines the procedural framework necessary for managing drug formulary decisions while ensuring that both cost-effective and clinically effective pharmaceutical policies are adopted within the DoD's healthcare system. The emphasis is on strategic management of new medications and their implications for patient access and cost containment in military healthcare settings.

The Department of Defense (DoD) issued a request for quotes (RFQ) for newly approved antidepressants and non-opioid pain syndrome agents, specifically focusing on the serotonin antagonist and reuptake inhibitor subclass. This announcement is tied to the upcoming Pharmacy and Therapeutics (P&T) Committee meeting scheduled for May 7-8, 2025, with quotes due by April 17, 2025. Each drug is listed with its National Drug Code (NDC), strength, dosage form, package size, and pricing information. Multiple drugs, identified as either uniform or non-formulary, are included, although no quotes have yet been submitted as indicated by "NO QUOTE" entries. The committee aims to review these agents for potential inclusion in TRICARE pharmacy benefits and to evaluate any necessary prior authorization processes. The document emphasizes the importance of participating manufacturers submitting complete quote information along with executed signature pages. Additionally, the P&T Committee may designate agents for special reimbursement strategies or consider preferential status for non-generic drugs, impacting cost-sharing classifications. The overall purpose of the document is to facilitate the procurement of pharmaceuticals under the DoD’s pharmacy benefit program, ensuring a structured approach for evaluation and pricing.

The Department of Defense (DoD) is preparing for a Pharmacy and Therapeutics (P&T) Committee meeting scheduled for May 7-8, 2025, focusing on oncological agents. Quotes for newly approved drugs are due by April 17, 2025. The document outlines multiple drug entries, emphasizing the distinction between uniform formulary and non-formulary agents, with notes indicating that no quotes have been submitted for any drugs listed. Key considerations include the potential for prior authorization (PA), designation of non-step preferred status for agents without submitted requests for quotation, and the opportunity for preferential treatment of non-generic pharmaceuticals in the formulary. An additional discount program is highlighted for tiered reimbursement structures, encouraging manufacturers to provide pricing that adheres to federal regulations, including the Federal Ceiling Price (FCP) metrics. The document underscores the importance of proper quote submission, noting the need for executed signature pages and adherence to specified pricing protocols, thereby ensuring compliance and facilitating the DoD's procurement processes for these critical oncology medications. This initiative reflects the government's commitment to managing healthcare costs while ensuring access to vital pharmaceutical treatments for military personnel and beneficiaries.

The document outlines the upcoming Department of Defense (DoD) Pharmacy and Therapeutics (P&T) Committee Meeting scheduled for May 7-8, 2025, focusing specifically on the class of "Targeted Immunomodulatory Biologics," with a subclass of "Interleukin 23." It emphasizes the importance of submitting quotes for newly approved drugs by the deadline of April 17, 2025. Key notes highlight that prior authorization may be required, and some drugs could be positioned with preferential status to encourage the use of high-value products. The document also includes provisions for step therapy requirements, indicating that patients must trial preferred agents before eligible for non-preferred options. Additionally, manufacturers are advised to ensure their submissions are complete, including executed signature pages. The P&T Committee is considering removing step preferences for specific conditions, as well as designating non-submitted agents as non-step preferred. The document reinforces the commitment to optimizing formulary management while balancing cost and availability for military treatment facilities under the TRICARE pharmacy benefit program.

The document outlines the upcoming Pharmacy and Therapeutics (P&T) Committee meeting scheduled for May 7-8, 2025, focusing on newly approved drugs classified as "Metabolic Agents - Miscellaneous." It indicates a deadline for quotes to be submitted by April 24, 2025. The document contains multiple appendices detailing Blanket Purchase Agreements and Additional Discount Programs for various drugs, which include National Drug Code (NDC) identifiers and stipulate submission requirements for vendors. Each Appendix discusses the required information for drugs that could potentially receive preferential reimbursement status or be excluded from the TRICARE benefit program. It emphasizes the potential for prior authorization (PA) for certain agents and outlines the conditions under which drugs may be categorized as non-step preferred. Notably, the summary indicates that certain agents could be designated as low-value, suggesting a shift in cost-sharing models to promote the use of higher-value alternatives. The document serves as a critical component for manufacturers aiming to participate in government pharmaceutical contracts while ensuring compliance with federal healthcare regulations. Overall, it sets guidelines for pricing and participation in the government's procurement processes for metabolic agents.

The Department of Defense (DoD) is preparing for a Pharmacy and Therapeutics (P&T) Committee meeting scheduled for May 7-8, 2025, focusing on new oncological agents. Manufacturers are invited to submit quotes for the newly approved drugs by April 17, 2025. The form emphasizes various categories and pricing scenarios for drugs included in the Uniform Formulary, specifying whether each product is uniform or non-formulary. Potential candidates may be selected for special reimbursement methods to encourage high-value product usage. The document outlines procedural requirements, including the need for manufacturers to submit fully executed signatures with their quotes, and provides details on tiered pricing structures for TRICARE retail refunds. It also notes that prior authorization may apply for certain medications and mentions that non-step preferred designations could affect agents with submitted RFQs that are not selected. The emphasis on cost containment and high-value drug use highlights the DoD's commitment to optimizing healthcare expenditures while ensuring access to necessary treatments for military personnel. This initiative falls within larger government efforts to balance pharmaceutical spending with patient care needs within the TRICARE system.

The Department of Defense (DoD) is preparing for its Pharmacy and Therapeutics (P&T) Committee Meeting scheduled for May 7-8, 2025, focusing on Alzheimer's Agents as part of a Blanket Purchase Agreement (BPA). Drug quotes for newly approved Alzheimer's medications are due by April 17, 2025. Each drug is categorized as either Uniform Formulary or Non-Formulary without quoted prices submitted in the provided documentation. The agreement includes provisions for potential pricing scenarios, allowing the P&T Committee to recommend special reimbursement methods to promote high-value products and potentially restrict low-value options. Additionally, the committee may designate some agents non-preferred after-step for step therapy guidelines or consider excluding them from the TRICARE pharmacy benefit. Manufacturers are reminded to submit necessary documentation alongside their quotations. The meeting will review the Alzheimer's medications, with the possibility of implementing prior authorizations and varying status based on drug value and cost outcomes. This process aligns with federal regulations aiming for efficient pharmaceutical management within military healthcare.

The Department of Defense's Defense Health Agency (DHA) has issued a Request for Quotation (RFQ) related to pharmaceutical agents for the Uniform Formulary (UF) as mandated by law (10 U.S.C. § 1074g). This RFQ is geared toward establishing Blanket Purchase Agreements (BPA) and Additional Discount Program (ADP) agreements for pharmaceutical agents eligible for the TRICARE pharmacy benefit. Manufacturers can submit offers to provide competitive quotes based on clinical and cost-effectiveness evaluations by the DHA's Pharmacy and Therapeutics Committee. The process involves manufacturers registering to submit quotes, which must include a signed quote and National Drug Code (NDC) price list. Key sections of the document outline the instructions for submission, evaluation criteria, and conditions regarding adherence to Federal pricing standards. The proposal also details the terms for refunds linked to retail pharmacy utilization and specifies the responsibilities of the manufacturers. Overall, the document emphasizes transparency and competitive pricing, aiming to ensure the provision of effective pharmaceutical benefits to military personnel and their families while complying with federal regulations.